OrbiMed’s Arcturus Therapeutics ARCT Stock Holding History

OrbiMed’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-848,503	Closed	-$28.7M	–	174
2021 Q2	$28.7M	Sell	848,503 -358,383	-30%	-$12.1M	0.29%	82
2021 Q1	$49.8M	Sell	1,206,886 -73,200	-6%	-$4.36M	0.47%	60
2020 Q4	$55.5M	Buy	1,280,086 +661,500	+107%	+$44.8M	0.49%	59
2020 Q3	$26.5M	Buy	618,586 +379,400	+159%	+$18.8M	0.33%	77
2020 Q2	$11.2M	Buy	+239,186	New	+$8.24M	0.16%	95

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $127M AUM

OrbiMed's ARCT Position: Q3 2021 in Review

OrbiMed sold out of Arcturus Therapeutics (ARCT) in Q3 2021, closing a stake of 848,503 shares — an estimated $28.7M sold.

OrbiMed first reported a position in ARCT in Q2 2020 and held it in 5 quarters. The position peaked at $55.5M in Q4 2020. 156 funds tracked by Wall St. Rank hold ARCT as of Q3 2021.

OrbiMed reported no remaining Arcturus Therapeutics position as of Q3 2021 after selling out during the quarter.
OrbiMed sold 848,503 Arcturus Therapeutics shares in Q3 2021, an estimated $28.7M.
OrbiMed first reported a position in Arcturus Therapeutics in Q2 2020 and held it in 5 quarters.
OrbiMed's Arcturus Therapeutics position peaked at $55.5M in Q4 2020.
156 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2021.

Based on OrbiMed's 13F filing for Q3 2021, filed 15 Nov 2021.